EMBO Mol Med

Publications

Infrastructure Units

ISSN	1757-4684
ISSN-L	1757-4676
IUID	ebdcb44712f24b9c9b39143e381696a5
Modified	2020-11-27T13:14:06.958Z
Created	2017-05-09T09:12:31.821Z

Year 2022

PubMed DOI Crossref

The onset of PI3K-related vascular malformations occurs during angiogenesis and is prevented by the AKT inhibitor miransertib.

Kobialka P, Sabata H, Vilalta O, ..., Castillo SD, Graupera M

EMBO Mol Med 14 (7) e15619 [2022-07-07; online 2022-06-13]

Bioinformatics Compute and Storage [Service]

Year 2020

PubMed DOI Crossref

Ribonucleotide reductase inhibitors suppress SAMHD1 ara-CTPase activity enhancing cytarabine efficacy.

Rudd SG, Tsesmetzis N, Sanjiv K, ..., Helleday T, Herold N

EMBO Mol Med 12 (3) e10419 [2020-03-06; online 2020-01-17]

Chemical Biology Consortium Sweden (CBCS) [Collaborative]

Year 2019

PubMed DOI Crossref

Anti-tumor effects of PIM/PI3K/mTOR triple kinase inhibitor IBL-302 in neuroblastoma.

Mohlin S, Hansson K, Radke K, ..., von Stedingk K, Bexell D

EMBO Mol Med 11 (8) e10058 [2019-08-00; online 2019-07-16]

NGI Uppsala (Uppsala Genome Center) [Service] National Genomics Infrastructure [Service] Structural Proteomics [Service]

Year 2014

PubMed DOI Crossref

Affinity proteomics within rare diseases: a BIO-NMD study for blood biomarkers of muscular dystrophies.

Ayoglu B, Chaouch A, Lochmüller H, ..., Nilsson P, Al-Khalili Szigyarto C

EMBO Mol Med 6 (7) 918-936 [2014-07-00; online 2014-06-13]

Affinity Proteomics Stockholm [Collaborative]

Year 2013

PubMed DOI Crossref

CDK-mediated activation of the SCF(FBXO) (28) ubiquitin ligase promotes MYC-driven transcription and tumourigenesis and predicts poor survival in breast cancer.

Cepeda D, Ng HF, Sharifi HR, ..., Larsson LG, Sangfelt O

EMBO Mol Med 5 (7) 1067-1086 [2013-07-00; online 2013-06-19]

Tissue Profiling

Add publication

Multiple copies

SciLifeLab Data Centre

Publications 7.2.7